Of note, impairment of glycolysis has been shown in earlier studies to be associated with activated oncogenes (such as RAS, or MYC) and mutant tumor suppressors (such as TP53) [45, 49, 50] and such mutations have been reported to occur more frequently in low-grade rather than high-grade gliomas [51–53]. This evidence concerns the gene TP53 and central nervous system cancer.